Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism

Table 1 EC₅₀ of the 14 compounds

Compound	Unit	HT-29 EC50	MCF-7 EC50	MDA-MB-231 EC50
Prima-1met	[μM]	64.9	18.1	71.1
Nutlin-3	[μM]	28.8	6.0	39.2
SJ172550	[μM]	15.4	15.6	229.5
YM155	[nM]	50.9	2.54	23.6
6-Shogaol	[μM]	29.7	148.9	503.5
Pictilisib	[μM]	19.8	0.16	532.8
InoC2PAF	[μM]	7.4	9.5	91.7
PX-478	[μM]	77.4	15.92	164.3
DCA	[mM]	34.9	40.7	48.7
CB-839	[μM]	3.3	6.0	13.3
3-BP	[μM]	15.6	110.7	554.8
Metformin	[mM]	6.9	13.4	100
NHI-2	[μM]	32.7	29.82	26.14
Cisplatin	[μM]	549.8	84.35	484.5

Cells were seeded into a 96 well plate at a density of 1.5 (HT-29, MDA-MB) and 0.5 × 10⁴/well (MCF-7), incubated 24 h to a confluence of 50%, then incubated with increasing concentrations of the 14 selected drugs for 48 h. Then, viability was assessed using the MTT-Assay and EC₅₀ was calculated using Graphpad Prism

ISSN: 1471-2407